Clinical evidence currently suggests confirmed drug interactions are uncommon, although digestive side effects may overlap temporarily
It is temporary and can be managed by staying well hydrated, maintaining oral hygiene, eating balanced meals, and following a gut-friendly diet
It is commonly discussed in wellness and recovery-focused peptide protocols involving mobility support, recovery support, tissue support, and exercise recovery goals
These therapies not only contribute to substantial and sustained weight loss but also improve cardiovascular health markers, which is crucial for obese individuals facing elevated risks of heart disease
The analysis found that: At 12 months, Omada members largely maintained their weight at GLP-1 discontinuation, with an average 0.8% weight change At 12 months, 63.2% of members maintained or continued to lose weight At 6 and 9 months, Omada members demonstrated 0.03% and 0.6% average weight change, respectively These findings suggest that Omada can play an integral role in supporting members during important transitions in their GLP-1 journey, including helping members maintain their weight well after GLP-1 discontinuation.
